新辅助疗法是某些早期和局部晚期乳腺癌治疗的基石。事实上，使用新辅助化疗可以获得许多优势，包括实现更为保守的干预、评估体内治疗反应、根据对治疗反应程度的调整调节后续治疗的强度、以及获得有关遗传学的手术信息。然而，在新辅助细胞毒性疗法结束时，不可能立即进行手术，因为由于系统性治疗本身所导致的毒性，特别是血液学方面，需要一定的恢复时间。同时，结束新辅助疗法和手术之间不应该过长的时间。这篇系统文献综述的目的是根据系统综述的方法，总结有关此主题的最相关文献数据。版权所有©2023 Elsevier B.V.。保留所有权利。

Neoadjuvant therapy is a cornerstone of some early and locally advanced breast cancer treatment. The use of neoadjuvant chemotherapy, in fact, allows to obtain numerous advantages, including allowing a more conservative intervention, evaluating the in vivo response to therapy, modulating the intensity of subsequent treatments based on the degree of response to therapy and allowing to surgery with information on genetics. However, at the end of neoadjuvant cytotoxic therapy it is not possible to carry out surgery immediately, as a certain amount of time is required for recovery from toxicity, especially haematological, due to the systemic therapy itself. At the same time, it is intuitive that too much time must not pass between the end of neoadjuvant therapy and surgery. The goal of this systematic literature review is to summarize the most relevant literature data on this topic, selected and extracted according to the methodology of systematic reviews.Copyright © 2023 Elsevier B.V. All rights reserved.